India has introduced stricter testing and observation requirements for veterinary medicines, including biological products, with a particular focus on inactivated foot-and-mouth disease vaccines. According to reports from Mint, under the revised norms, manufacturers must administer a double dose of the vaccine to pigs and observe them for 14 days to detect any adverse reactions or contamination. The rules also introduce the monocyte activation test for biological products to detect pyrogens—substances that can trigger fever and signal contamination—during the manufacturing process.
The changes are part of the 10th edition of the Indian Pharmacopoeia, which came into effect on 1 July. As reported by Mint, the Indian Pharmacopoeia is the country's official book of quality standards for medicines, vaccines, biological products, and pharmaceutical ingredients. The changes have implications for India's roughly $250 million veterinary vaccine market, as the country continues to contend with outbreaks of zoonotic diseases including Chandipura virus, West Nile virus, avian influenza, covid-19, fungal zoonoses, hantavirus, Lyme disease, mpox, rabies, Nipah virus and zoonotic tuberculosis. India has 535.78 million livestock animals, including 192.49 million cattle, 148.88 million goats, 109.85 million buffaloes, 74.26 million sheep, and 9.06 million pigs, according to the 20th Livestock Census.
The World HPLC Pumps market is entering a sustained expansion phase, with demand projected to grow at a compound annual rate of 5.8% from 2026 to 2035, reaching a market index of 175 relative to 2025. This growth is underpinned by structural shifts in pharmaceutical R&D, bioprocessing scale-up, and tightening regulatory frameworks across global quality control laboratories. HPLC pumps—precision positive-displacement devices delivering pulse-free solvent flow at pressures up to 1,300 bar—are essential for high-performance liquid chromatography applications in drug development, clinical diagnostics, food safety testing, and environmental monitoring. Asia-Pacific dominates with 38% share, led by China, India, Japan, and South Korea, driven by rapid pharmaceutical R&D growth and increasing food/environmental testing demand.
The commission has simultaneously revised quality standards for several human medicines, tightening requirements for the detection, identification and control of impurities in commonly used drugs. According to Mint, for the antiviral drug aciclovir, testing laboratories must now use revised analytical methods to verify reference standards. For the antibiotic clarithromycin, the updated standards tighten impurity limits, requiring that no more than four specified impurities exceed the 0.4% threshold. The pharmacopoeia also revises quality specifications for the blood pressure medicine azilsartan medoxomil to strengthen control over impurities during manufacturing.
